Company Description
Imunon, Inc., a clinical-stage biotechnology company, develops immunotherapies and next-generation vaccines.
The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stacy R. Lindborg Ph.D. | President, Chief Executive Officer and Director |
| Michael H. Tardugno | Executive Chairman |
| David G. Gaiero CPA | Chief Financial Officer |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Timothy J. Tumminello CPA | Chief Accounting Officer and Controller |
| Susan Mary Eylward | General Counsel and Corporate Secretary |
| Kristin Longobardi M.B.A. | Senior Vice President of Strategic Operations |
| Dr. Douglas V. Faller M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |